TY - CHAP
T1 - The in vivo topography of cortical changes in healthy aging and prodromal Alzheimer's disease
AU - Prestia, Annapaola
AU - Baglieri, Annalisa
AU - Pievani, Michela
AU - Bonetti, Matteo
AU - Rasser, Paul E.
AU - Thompson, Paul M.
AU - Marino, Silvia
AU - Bramanti, Placido
AU - Frisoni, Giovanni B.
N1 - Funding Information:
This work was supported by Grants Ex Art 56 533 F/B 1 and PS-Neuro Ex 56/05/11 (Italian Ministry of Health), and supported in part by a grant from the Italian Ministry of Health, Analisi dei Fattori di Rischio e di Potenziali Elementi Predittivi di Danno Neurodegenerativo Nelle Sindromi Parkinsoniane number 502/92.
Funding Information:
P.T. is supported, in part, by NIH Grants R01 EB008281, EB008432, EB007813, AG036535, and AG020098, and by the NIBIB, NCRR, NIA, and NICHD, agencies of the U.S. National Institutes of Health.
PY - 2013
Y1 - 2013
N2 - Background: Gray matter atrophy is regarded as a valid marker of neurodegeneration in Alzheimer's disease (AD), but few studies have investigated in detail the topographic changes associated with normal aging. In addition, few studies have compared the changes in the earliest clinical stage of AD (prodromal AD (pAD)) with those of healthy aging. Here we aimed to investigate the topographical distribution of age-related cortical atrophy and to compare it with that associated with prodromal and estabilished AD. Methods: Structural T1-weighted high-resolution brain magnetic resonance imaging scans were acquired from 60 healthy volunteers (20 young adults, YA: age 32.7 ± 4.5 years; 40 elderly subjects, HE: age 71.3 ± 6.2 years), 16 mild cognitive impairment subjects who converted to AD within 2 years (prodromal AD, pAD: age 72.8 ± 5.4), and 20 mild to moderate AD patients (mAD, age 72.5 ± 10.3). Cortical gray matter differences were investigated using a surface-based anatomical mesh modeling technique (cortical pattern matching) and region-of-interest (ROI) analyses based on hypothesized brain networks taught to have a functional and a structural link to each other. Differences in cortical atrophy were assessed between groups, as well as the effect of age within groups. Results: HE compared to YA showed a 10-30% deficit in cortical gray matter in widespread frontal, temporal, and parietal regions (p = 0.0001 by permutation testing), 6-13% loss in the visual and sensorimotor cortices (p < 0.01) and up to 13% loss in the direct hippocampal pathway ROIs (p < 0.001). pAD patients showed on average 8-9% cortical loss compared to HE (p < 0.0001), mainly in the left (up to 6% loss, p = 0.06) and right polysynaptic hippocampal pathway ROIs (up to 8% loss, p = 0.01), and in the left and right olfactory/orbitofrontal cortex (up to 12-15% loss, p < 0.001). The pattern of cortical atrophy in mAD versus HE was similar to that in pAD, but was more severe in the direct hippocampal pathway ROIs and sensorimotor, visual and temporal cortices (13-15% loss compared with HE, p < 0.0001). Conclusion: Gray matter loss occurs during aging with rates of atrophy even more severe than that observed during the course of AD. These changes may be caused by normal mechanisms. In pAD, cortical atrophy due to disease is milder than that due to aging, maybe resulting from a slowed down velocity of cell loss, but affects specific brain areas. These findings are consistent with the view that AD is not merely accelerated aging.
AB - Background: Gray matter atrophy is regarded as a valid marker of neurodegeneration in Alzheimer's disease (AD), but few studies have investigated in detail the topographic changes associated with normal aging. In addition, few studies have compared the changes in the earliest clinical stage of AD (prodromal AD (pAD)) with those of healthy aging. Here we aimed to investigate the topographical distribution of age-related cortical atrophy and to compare it with that associated with prodromal and estabilished AD. Methods: Structural T1-weighted high-resolution brain magnetic resonance imaging scans were acquired from 60 healthy volunteers (20 young adults, YA: age 32.7 ± 4.5 years; 40 elderly subjects, HE: age 71.3 ± 6.2 years), 16 mild cognitive impairment subjects who converted to AD within 2 years (prodromal AD, pAD: age 72.8 ± 5.4), and 20 mild to moderate AD patients (mAD, age 72.5 ± 10.3). Cortical gray matter differences were investigated using a surface-based anatomical mesh modeling technique (cortical pattern matching) and region-of-interest (ROI) analyses based on hypothesized brain networks taught to have a functional and a structural link to each other. Differences in cortical atrophy were assessed between groups, as well as the effect of age within groups. Results: HE compared to YA showed a 10-30% deficit in cortical gray matter in widespread frontal, temporal, and parietal regions (p = 0.0001 by permutation testing), 6-13% loss in the visual and sensorimotor cortices (p < 0.01) and up to 13% loss in the direct hippocampal pathway ROIs (p < 0.001). pAD patients showed on average 8-9% cortical loss compared to HE (p < 0.0001), mainly in the left (up to 6% loss, p = 0.06) and right polysynaptic hippocampal pathway ROIs (up to 8% loss, p = 0.01), and in the left and right olfactory/orbitofrontal cortex (up to 12-15% loss, p < 0.001). The pattern of cortical atrophy in mAD versus HE was similar to that in pAD, but was more severe in the direct hippocampal pathway ROIs and sensorimotor, visual and temporal cortices (13-15% loss compared with HE, p < 0.0001). Conclusion: Gray matter loss occurs during aging with rates of atrophy even more severe than that observed during the course of AD. These changes may be caused by normal mechanisms. In pAD, cortical atrophy due to disease is milder than that due to aging, maybe resulting from a slowed down velocity of cell loss, but affects specific brain areas. These findings are consistent with the view that AD is not merely accelerated aging.
KW - Aging
KW - Alzheimer's disease
KW - Atrophy
KW - Cortical pattern matching
KW - Gray matter loss
UR - https://www.scopus.com/pages/publications/84876994650
U2 - 10.1016/B978-0-7020-5307-8.00004-1
DO - 10.1016/B978-0-7020-5307-8.00004-1
M3 - Chapter
C2 - 24053032
AN - SCOPUS:84876994650
SN - 9780702053078
T3 - Supplements to Clinical Neurophysiology
SP - 67
EP - 80
BT - Supplements to Clinical Neurophysiology
PB - Elsevier B.V.
ER -